Compare Home Depot Inc (HD) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Home Depot Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Home Depot Inc trades at $302.02 (market cap $294.83B), while Spyre Therapeutics Inc. Common Stock trades at $78.35 (market cap $7.35B). The key difference: Home Depot Inc is far larger — about 40.1× Spyre Therapeutics Inc. Common Stock's market cap, and Home Depot Inc pays a 3.15% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Home Depot Inc for 139 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| HD | SYRE | |
|---|---|---|
Market Cap | $294.83B | $7.35B |
Volume | 4,653,976 | 1,624,631 |
Sector | Consumer Cyclical | Health |
52-Week High | $391.90 | $108.92 |
52-Week Low | $281.15 | $22.18 |
Typical Hold Time | 139 Days | 0 Days |
Enterprise Value | $355.31B | $6.35B |
Dividend Yield | 3.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Home Depot (HD) trades at $293.92, up 1.14% on the day, with a bearish technical signal and mixed sentiment. The stock shows strong profitability with a net margin of 8.41% and ROE of 104.3%, but faces margin compression and weak big-ticket demand. Recent earnings beats and a $2.33 dividend highlight operational resilience amid housing market headwinds.
The outlook is cautious; analyst consensus is bullish with a $379.93 price target, but rising mortgage rates and competitive pressures pose risks. Upside hinges on Pro segment growth and housing recovery, while downside risks include sustained margin pressure and economic slowdown.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Home Depot Inc
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
